Our lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplant (HCT). We are also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. We have developed and are continuing to build the ImmunoBank, our repository of therapeutic TCRs that recognize diverse targets and are associated with multiple (human leukocyte antigen) HLA types, to provide customized multiplexed TCR-T therapies for patients with a variety of solid tumors.

TScan was founded in early 2018 to discover and develop transformational TCR-Ts using a novel T cell target discovery platform developed by Stephen Elledge, Ph.D., and Tomasz Kula, Ph.D., at Brigham and Women’s Hospital and Harvard Medical School. Our approach is based on the central premise that we can learn from patients who are winning their fight against cancer in order to treat those who are not. This technology is extremely versatile and is applicable across multiple therapeutic areas beyond cancers, including autoimmune disorders and infectious diseases.

Meet our expert management.